Proteome launches San Diego lab operations

The AIM-traded firm said the facility has the latest generation Orbitrap Ascend Tribrid mass spectrometry and automated sample preparation platforms.

Situated in one of the largest biotech hubs in the US, the laboratory was strategically located to meet the increasing demand from US-based clients seeking proteomics solutions for drug development initiatives, the board explained.

It noted that the San Diego biotech hub had seen significant investments totalling $17.2bn and received $6bn in funding from the US National Institute of Health in the 2023 financial year.

Proteome said the new laboratory eliminated the need to transport samples internationally, making its services more appealing to customers, including pharmaceutical companies and academic institutions.

"I am delighted that we are able to open our doors to serve arguably the world's largest biotechnology hub in California," said Dr Ian Pike, president of Proteome Sciences US.

"Providing easier access to our US customers and with innovations including TMTpro 32plex and single cell proteomics (SCP), delivered from both our dedicated laboratories in the US and Europe we are well set to continue our leading role in provision of tools, assays and services in proteomics research as it grows in importance to enhance pharmaceutical research and drug development."

Reporting by Josh White for Sharecast.com.